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Abstract
Background: Leptin, a hormone-like peptide secreted by adipose tissue, is a strong correlate
of obesity. Conflicting data exist concerning leptin as an independent risk factor of coronary
artery disease. The aim of the study was to assess the relationship between leptin and obesity
and cardiovascular risk factors in men with acute myocardial infarction.
Methods: Two groups of patients who had experienced their first acute myocardial infarction
were analysed: 40 obese and 40 non-obese men. Waist and hip circumferences, waist-to-hip ratio,
C-reactive protein (CRP), uric acid, fasting glucose, lipid profile and leptin were measured.
Results: Mean leptin was significantly higher in obese than in non-obese patients (46.7 ng/ml –
– 18.7 vs. 15.6 ng/ml – 11.9; p < 0.01). Leptin levels correlated positively with all anthropo-
metric measurements, fasting glucose, triglyceride levels, CRP and uric acid and negatively
with HDL-cholesterol.
Conclusions: In patients with acute myocardial infarction, obesity is related to increased
leptin. The subcutaneous fat compartment seems to be an important determinant of plasma
leptin concentration. Leptinemia is associated with several biochemical disorders, suggesting
that leptin may be a pathogenetic factor in cardiovascular disease. (Cardiol J 2007; 14: 252259)
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Introduction
Obesity carries a cluster of traditional cardio-
vascular risk factors, such as hypertension, dyslip-
idemia and diabetes, and factors associated with
atherogenesis, namely elevated levels of uric acid and
C-reactive protein (CRP) [16]. Leptin is a peptide
produced by adipose tissue and is a strong correlate
of obesity [711]. The amount of leptin synthesised
and secreted is known to increase in proportion to the
accumulation of body fat mass [9, 12, 13].
Recent studies on body weight regulation sug-
gest a dual role of leptin in human physiology. Un-
der conditions of steady-state energy balance lep-
tin is an index of the amount of triglyceride stored
in adipose tissue. In contrast, during fasting or over-
feeding it is a sensor of energy balance. In this acute
regulation leptin becomes an afferent component of
a feedback loop to preserve the internal level of
body fat content [14, 15].
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Because in the vast majority of cases human
obesity is characterised by hyperleptinemia, it ap-
pears that obese individuals are insensitive to their
endogenous leptin [16]. The possible explanations
for the leptin resistance are impaired brain access
to leptin, disorder of the leptin receptor, signalling
cascade or a leptin transducer system. Conflicting
data exist concerning leptin as an independent risk
factor of coronary artery disease and cardiovascu-
lar events [7, 1719]. Increased serum leptin con-
centrations have been observed in patients with
angina pectoris and myocardial infarction [20, 21].
The mechanisms leading to its impact on cardiovas-
cular dysfunction are complex. Leptin enhances
sympathetic nervous tone, which increases vascu-
lar tone and blood pressure, but this action is coun-
ter-balanced by its direct and indirect peripheral
vasorelaxation action [22, 23]. Evidence derived
from experimental studies suggests that selective
tissue resistance to the satiety and weight-reduc-
ing effects of leptin along with its preserved sym-
pathoexcitatory actions is a possible deleterious
pathophysiological factor [24]. Moreover, in vascu-
lar endothelial cells chronic hyperleptinemia induc-
es intra-cellular signalling, which results in oxida-
tive stress and may activate the atherogenic proc-
ess [25]. Conflicting data exist on the widely studied
association between high leptin concentration and
metabolic complications.
The aim of the study was to assess the rela-
tionship of blood leptin concentration to the anthro-
pometric parameters and cardiovascular risk factors
in men with acute myocardial infarction (AMI) treat-
ed with primary coronary intervention (PCI).
Methods
Study population
From a cohort of patients who had experienced
their first AMI and who had been successfully treat-
ed with PCI (TIMI flow grade 3, residual stenosis
< 30%), 40 obese men aged £ 65 years, who ad-
mitted to having been obese for at least 5 years,
were selected for the study group and 40 non-obese
men, matched to the obese group for age and local-
isation of the AMI, were included in the study as
a control group.
Insulin therapy before blood sampling for lep-
tin measurement was considered an exclusion cri-
terion. Additional exclusion criteria were applied
owing to requirements for the acquisition of
echocardiographic parameters which are unreport-
ed in this study. These conditions were atrial fibril-
lation, atrioventricular or bundle branch block,
temporary or permanent stimulation and significant
valvular heart disease.
Anthropometric measurement
clinical definitions and treatment
Diagnosis of AMI was based on the clinical
symptoms, electrocardiographic signs and elevation
of myocardial necrotic markers. All patients received
aspirin and those who underwent stenting were con-
comitantly treated with an additional antiplatelet
agent. Heparin was infused during the procedure.
Glycoprotein IIb/IIIa inhibitor was administered to
a similar proportion of patients in each group. Phar-
macological treatment with aspirin, clopidogrel, stat-
ins, b-blockers, angiotensin II inhibitors, nitrates and
diuretics was similar in both groups.
A body mass index (BMI), calculated as the body
weight divided by the square of the height (kg/m2),
of 30 was used as a marker of obesity, while patients
with a BMI below 25 were designated as non-obese.
Weight and height were measured on the 3rd or 4th
day after admission, while the subjects were fast-
ing and wearing only their undergarments. Waist
circumference (WC), a measure of subcutaneous
plus visceral fat, was measured at the widest diam-
eter between the xiphoid process of the sternum
and the iliac crest. Hip circumference (HC), repre-
senting subcutaneous fat alone, was measured at
the widest diameter over the greater trochanters.
The waist-to-hip ratio (WHR) was than calculated.
Systolic and diastolic blood pressure (SBP, DBP)
was measured before blood sampling.
The study was approved by the Internal Ethics
Committee of the Medical University of £ód, and
each patient gave his informed consent.
Laboratory measurements
CRP and uric acid were assessed as part of
a complex analysis of the samples of blood taken
upon admission to the hospital. Fasting glucose,
lipid profile and leptin levels were determined from
the blood drawn the following day. Plasma triglyc-
erides (TG) and total cholesterol (TCH) were meas-
ured by enzymatic analytical chemistry. HDL-cho-
lesterol (HDL-CH) was precipitated using dextran-
sulphate and measured enzymatically, while
LDL-cholesterol (LDL-CH) was calculated using
the Friedewald equation: LDL-CH = TCH  (TG/5)
HDL-CH. Impaired lipid metabolism was diag-
nosed if at least one of the following disorders was
present: hypercholesterolemia (TCH > 200 mg/dl),
hypertriglicerydemia (TG > 150 mg/dl), high LDL-CH
(LDL > 100 mg/dl) or low HDL-CH (HDL-CH <
< 40 mg/dl). Plasma glucose concentrations were
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measured with the oxidise method, uric acid with
the colorimetric method and CRP concentrations
with an immunotubidimetric assay.
Plasma samples for leptin concentration meas-
urements were frozen at 70° until analysis with
a sandwich enzyme-linked immunosorbent assay
(ELISA).
Statistical analysis
Descriptive statistics are expressed as mean –
– standard derivation. Variables were log-trans-
formed before statistical analysis if necessary. Com-
parisons between the two groups were performed
using the two-tailed, non-paired Students t-test or
the Mann-Whitney test, as appropriate. Categori-
cal variables are presented as numbers and percent-
ages of patients and comparisons between groups
were analysed with the c2 test. Associations be-
tween the parameters analysed were examined
using Spearmans correlation coefficient. A p value
of < 0.05 was considered to be statistically signifi-
cant. Statistical analysis was performed using Sta-
tistica software (version 5.0).
Results
The clinical characteristics and anthropometric
measurements of the obese and non-obese patients
are shown in Table 1. The occurrence of hyperten-
sion, diabetes, smoking and hypercholesterolemia
was similar in the two groups. SBP, the proportion
of patients with HDL-CH < 40 mg/dl and TG <
< 150 mg/dl and all the anthropometric measure-
ments made (BMI, WC, HC, WHR) were significant-
ly higher in the obese group than in the control group.
The mean values of the biochemical parame-
ters are presented in Table 2. In the obese patients
the values of TG, fasting glucose and CRP were
significantly higher than in the non-obese patients,
whereas HDL-CH levels were lower.
Table 1. Clinical characteristics and anthropometric measurements of the study groups.
Obese (n = 40) Non-obese (n = 40) p
Age 53.6–7.39 54.4–6.62 NS
Hypertension 25 (62.5%) 18 (45%) NS
Systolic blood pressure [mm Hg] 124.1–9.32 119.0–13.2 < 0.05
Diastolic blood pressure [mm Hg] 75.5–6.18 73.1–8.37 NS
Diabetes mellitus 11 (27.5%) 7 (17.5%) NS
Total cholesterol > 200 mg/dl 27 (67.5%) 26 (65%) NS
Triglicerydes > 150 mg/dl 24 (60%) 13 (32.5%) < 0.05
LDL-cholesterol > 100 mg/dl 36 (90%) 34 (85%) NS
HDL-cholesterol < 40 mg/dl 15 (37.5%) 5 (12.5%) < 0.01
Smoking 25 (62.5%) 27 (67.5%) NS
Body mass index [kg/m2] 32.2–1.96 23.8–1.40 < 0.0001
Waist circumference [cm] 111.9–7.52 88.1–7.09 < 0.0001
Hip circumference [cm] 108.3–6.73 91.4–7.67 < 0.0001
Waist-to-hip ratio 1.03–0.05 0.96–0.30 < 0.001
Table 2. Biochemical parameters in the study groups.
Obese (n = 40) Non-obese (n = 40) p
Fasting glucose [mg/dl] 110.1–14.5 94.8–10.3 < 0.001
Total cholesterol [mg/dl] 224.2–44.0 216.7–40.1 NS
LDL-cholesterol [mg/dl] 146.3–43.1 138.4–42.5 NS
Triglicerydes [mg/dl] 161.3–59.8 132.9–52.1 < 0.01
HDL-cholesterol [mg/dl] 45.6–11.9 51.6–12.3 < 0.05
C-reactive protein [mg/dl] 7.95–7.29 4.25–4.84 < 0.01
Uric acid [mg/dl] 6.11–1.48 5.66–1.47 NS
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The range of fasting plasma leptin concentra-
tions in this population was 0.8 to 75.8 ng/ml. Obese
patients had leptin levels approximately three times
higher than non-obese subjects (46.7 – 18.7 ng/ml vs.
15.6 – 11.9 ng/ml; p < 0.0001) (Fig. 1).
In our study association between age and lep-
tin concentration was not observed (r = 0.09, NS).
In the study group as a whole a significant correla-
tion was revealed between plasma leptin concentra-
tion and anthropometric parameters, the strongest
correlation being with waist circumference (Fig. 2).
A positive relationship was observed between lep-
tin and fasting glucose, TG, CRP and uric acid and
a negative relationship between leptin and HDL-CH.
Similar relations were noted between the anthro-
pometric measurements and the obesity related
risk factors analysed (Table 3).
Discussion
Age and gender
In our group of patients aged under 65 years
there was no independent relation between age and
leptin. This observation is in agreement with some
previous reports [18, 26, 27]. Ostlund et al. [13], in
patients aged 1880 years (mean 52.8 – 15.8 years),
revealed a weak inverse relationship between lep-
tin and age independently of body fat. They have
also shown that subjects aged over 60 years had
significantly lower plasma leptin concentrations
than younger ones. These results could suggest
a possible decrease in adipose tissue leptin produc-
tion and/or increase in plasma leptin clearance in
the elderly. In contrast with this a positive relation
of leptin with age has been revealed in other stud-
ies [12, 2830]. It has been suggested that an age-
related increase in fat mass can be a major confound-
ing factor because adiposity is a strong determinant
of leptin. Gender-specific differences in plasma lep-
tin concentration with ageing have also been ob-
served [3133].
Our study was designed for males in order to
avoid the impact of sex-related differences in the
location of the adipose tissue, the number of fat
cells, fat cell size and plasma leptin concentration
[9, 34]. The molecular mechanisms underlying the
regulation of adipose tissue mass distribution re-
mains poorly understood, although this is likely to
be regulated by hormonal factors, especially sex
steroids, glucocorticoids and insulin [9, 35, 36].
Obesity
The results of our study are in agreement with
previous reports documenting the relationship be-
tween obesity, as reflected by BMI, and plasma lep-
tin in various populations with different ranges of BMI
and in both sexes [711, 13, 17, 18, 26, 28, 29, 3739].
The independent relation of plasma leptin to fat
distribution is controversial. Both negative [9, 11, 26]
and positive [8, 27, 28, 40] relationships between
leptin and WHR have been reported. A thorough
analysis of the literature reveals that leptin is more
likely to be positively related to WHR in men and
negatively in particular groups of patients, including
the majority of women. This gender-related difference
could be explained by the presence of more abun-
dant subcutaneous fat in women and of visceral
fat in men. However, it has previously been estab-
lished that leptin secretion rates are higher in sub-
cutaneous than in visceral adipose tissue [4143]. It
has been reported that waist girth is likely to be
a more convenient anthropometric correlate of visceral
adipose tissue than WHR [44]. In our study to de-
termine the predominant site of release of leptin we
analysed correlations of leptin with WC represent-
ing both subcutaneous and visceral adipose tissue
and with HC as a measure of subcutaneous fat alone.
The significant positive correlation of leptin with WC
(r = 0.76, p < 0.0001) and HC (r = 0.74, p < 0.0001)
and suggests that secretion of leptin into the blood-
stream might be regulated both by visceral and sub-
cutaneous adipose tissue.
Biochemical disorders
Hyperleptinemia may coexist with other
proatherogenic factors typical for obesity. We found
a significant difference in leptin concentrations as
well as in TG, HDL-CH and fasting glucose between
Figure 1. The mean value of plasma leptin concentra-
tion in the study groups.
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Figure 2. The relation of leptin with anthropometric measurements.
Table 3. The relationship of leptin and anthropometric measurements to obesity-related risk factors.
Leptin Body mass Waist Hip Waist-to-hip
index circumference circumference ratio
Systolic blood pressure r = 0.17 r = 0.29 r = 0.23 r = 0.21 r = 0.23
NS p < 0.01  p < 0.05  NS p < 0.05
Diastolic blood pressure r = 0.12 r = 0.28 r = 0.18 r = 0.20 r = 0.14
NS p < 0.05 NS NS NS
Fasting glucose r = 0.46 r = 0.47 r = 0.50 r = 0.45 r = 0.40
p < 0.0001 p < 0.0001 p < 0.0001 p < 0.0001 p < 0.001
Total cholesterol r = 0.18 r = 0.001 r = 0.01 r = 0.04 r = 0.09
NS  NS  NS  NS  NS
HDL-cholesterol r = 0.27 r = 0.30 r = 0.39 r = 0.30 r = 0.35
p = 0.05  p < 0.01  p < 0.001  p < 0.05  p < 0.01
LDL-cholesterol r = 0.19 r = 0.03 r = 0.07 r = 0.002 r = 0.14
NS  NS  NS  NS  NS
Triglicerydes r = 0.31 r = 0.18 r = 0.22 r = 0.20 r = 0.16
p < 0.01  NS  p < 0.05  NS  NS
C-reactive protein r = 0.35 r = 0.40 r = 0.39 r = 0.22 r = 0.50
p < 0.01  p < 0.001  p < 0.0001  p < 0.05  p < 0.0001
Uric acid r = 0.28 r = 0.18 r = 0.23 r = 0.19 r = 0.18
p < 0.05  NS  p < 0.05  NS  NS
Leptin  r = 0.71 r = 0.76 r = 0.74 r = 0.57
 p < 0.0001  p < 0.0001  p < 0.0001 p < 0.0001
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the group of obese and non-obese patients. In the
present study, in agreement with most previous
reports, a positive correlation between plasma lep-
tin and TG [7, 8, 11, 18, 28, 45] and no correlation
between leptin and LDL-CH [18, 26, 27] was
revealed. There is disagreement among authors
concerning the relationship between plasma leptin
and HDL-CH. It is weak but negative in the group
studied by us and some previously reported series
of patients [8, 18, 45, 46], but no relationship was
revealed in other studies [7, 9, 26]. Thus the role
of plasma leptin as a good correlate of known lipid
risk factors for coronary artery disease is in ques-
tion. In our study, in consensus with other opinions,
leptin is positively related to the other coronary risk
factors namely fasting glucose [8, 11, 18, 28] and
uric acid [8, 11, 28, 47].
Recent studies have established that inflamma-
tion plays a fundamental role in mediating all stag-
es of atherosclerosis [48]. Adipose tissue secretes
various bioactive substances, including leptin, CRP,
IL-6, TNF-a, adiponectin and resistin [49, 50]. CRP
is not only a marker of the chronic inflammatory
process but also a molecule known to promote
atherogenesis [51]. It has been suggested that lep-
tin may be involved in the acute response to stress
and that in patients with AMI leptin is an acute-
phase reactant, facilitating metabolic adaptation to
increased demands during stress [52]. This view
may find support in the observation that leptin lev-
els increase in the 24 hours following myocardial
infarction [52, 53]. Moreover, pro-inflammatory
cytokines increase serum leptin concentration [54],
while, on the other hand, that leptin may produce
inflammation at the site of injection [53]. The pos-
sible explanation of this interaction is the resem-
blance of the leptin receptor and IL-6 receptor [55].
A positive association between leptin and CRP was
revealed in our group of patients and is in agree-
ment with previous studies in obese and non-obese
individuals, in groups of healthy subjects and in
patients with coronary artery disease [18, 29, 39,
56, 57], although it is denied by Fujimaki [58].
Not all these discrepancies and examples of
conflicting data can be explained by the simple im-
pact of one additional factor. The groups analysed
were different and inhomogeneous in terms of eth-
nicity, age, presence and degree of obesity, coex-
isting disease, the possible incidence of insulin and
leptin resistance and other co-factors. It has been
suggested that leptin in the physiological range
may play a protective role against cardiovascular
risk, whereas an elevated plasma leptin concen-
tration may act as a trigger and/or marker for
cardiovascular risk, possibly because of leptin re-
sistance [59, 60]. Future investigations, including
basic scientific research into the mechanisms of
leptin action and resistance, are called for to elu-
cidate the pathophysiological impact of leptin on
cardiac function.
Although the relationship between metabolic
risk factors and leptin [79, 11, 18, 2628, 4547]
and the relationship between metabolic risk fac-
tors and anthropometric parameters [16] have
been widely documented, there has been no inves-
tigation of whether there is any advantage in assess-
ing leptin over anthropometric parameters in terms
of the prediction of obesity-related metabolic risk
factors. In our study the correlation between met-
abolic risk factors and leptin did not achieve any
higher significance than that for anthropometric pa-
rameters (Table 3). This suggests that in general
practice blood sampling for leptin is not necessary,
unless it is identified as an independent risk factor.
Conclusions
1. In patients with acute myocardial infarction
obesity is related to increased plasma leptin
concentration.
2. Both subcutaneous and visceral fat compart-
ment seems to be an important determinant of
plasma leptin concentration.
3. Measurement of plasma leptin concentration
has no advantage over simple anthropometric
measurements in the prediction of obesity-re-
lated risk factors.
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